Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=-funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-funder_divisions", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-funder_divisions", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=-funder_divisions" }, "data": [ { "type": "Grant", "id": "6703", "attributes": { "award_id": "5IK6BX005691-02", "title": "BLRD Research Career Scientist Award Application", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-01", "end_date": "2026-03-31", "award_amount": null, "principal_investigator": { "id": 22435, "first_name": "Wendy B", "last_name": "Bollag", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1494, "ror": "https://ror.org/01ng1yh19", "name": "Charlie Norwood VA Medical Center", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1494, "ror": "https://ror.org/01ng1yh19", "name": "Charlie Norwood VA Medical Center", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "This application requests the appointment of Dr. Wendy Bollag, a Research Physiologist at the Charlie Norwood VA Medical Center in Augusta, Georgia and a Professor of Physiology at the affiliate institution (Augusta University), to the position of Research Career Scientist. In the past five years, Dr. Bollag has been productive, publishing 29 peer-reviewed articles and more than 10 invited reviews, book chapters and commentaries, with 52 peer-reviewed articles and 26 invited reviews, book chapters and commentaries in the past 10 years. Dr. Bollag’s research in cell signaling seeks to understand the role of particular signaling molecules in various cell processes; this research has led to interesting findings in her systems of interest, keratinocytes of the skin epidermis and zona glomerulosa cells of the adrenal gland, as well as extension of this knowledge to collaborative projects in other systems, including corneal wound healing. In the case of the skin and the adrenal gland, Dr. Bollag is interested in determining the signaling pathways that underlie keratinocyte proliferation and differentiation to form the epidermis under normal and pathological conditions, as well as those that regulate aldosterone production in the adrenal zona glomerulosa. In the past 10 years the Bollag laboratory has made significant progress in projects examining these two processes, as evidenced by the many publications for which she is the senior author. Dr. Bollag has also received as Principal Investigator (PI) or Co-PI three National Institutes of Health (NIH) R01 awards, one R29 award and one R21 award, five VA Merit Awards (three to support her work in skin, one to fund studies in the adrenal gland and one to support a new study in the cornea), a VA Research Career Scientist Award, two VA Shared Equipment Evaluation Program (ShEEP) awards and multiple state and intramural grant awards. She also recently received, as Contact Co-PI, an NIH T35 training award (with Co-PI, Dr. Carlos Isales) to recruit medical students from three Puerto Rican medical schools to perform summer aging research. She has also served as a Co-Investigator on several awards, including an NIH P01 Program Project Award with her colleague and collaborator of approximately 35 years, Dr. Isales, and as the Lead Mentor on a Department of Defense mentoring partnership award to Albany State University. Last year she received the Augusta University Research Institute Distinguished Investigator Award; she was also invited to give a symposium presentation at the 2019 annual meeting of Experimental Biology. This year she was invited to present in the Blank Forum at the 2020 annual meeting of the Society for Investigative Dermatology (which was unfortunately cancelled due to the pandemic) and to give a named lecture at the Oklahoma Center of Neuroscience (postponed until 2021 because of COVID-19), indicating that she is recognized for her research. Finally, Dr. Bollag is an individual who is engaged with the community and involved in giving back in service at the institutional, local and national levels. Thus, she mentors junior colleagues, including Dr. Debra Irsik, a recent VA Career Development Award recipient, provides educational service to the affiliate institution (for which she has received numerous awards), serves as a reviewer for multiple journals and participates in review panels for several national and international funding agencies, including the VA. Currently, Dr. Bollag is an Editorial Consultant for the Journal of Investigative Dermatology, the highest impact journal in the field of dermatology research, a Senior Editor for the Journal of Endocrinology and the Journal of Molecular Endocrinology and a member of the editorial boards of the Journal of Lipid Research and Molecular Pharmacology. Thus, Dr. Bollag is an established investigator and a recognized mentor, who would adeptly fulfill the responsibilities of the Research Career Scientist designation.", "keywords": [ "Adrenal Glands", "Affect", "Aging", "Aldosterone", "Angiotensin II", "Applications Grants", "Appointment", "Archives", "Award", "Back", "Biology", "Blood Circulation", "Book Chapters", "Book Reviews", "COVID-19", "Calpain", "Cell Maturation", "Cell model", "Cell physiology", "Cells", "Communities", "Cornea", "Corneal Injury", "Department of Defense", "Dermatologic", "Dermatology", "Differentiation and Growth", "Disease", "Endocrinology", "Epidermis", "Equipment", "Exploratory/Developmental Grant for Diagnostic Cancer Imaging", "Fellowship", "Funding", "Funding Agency", "Grant", "Hormones", "Hypertension", "Hypertriglyceridemia", "Individual", "Institution", "International", "Investigational Therapies", "Journals", "K-Series Research Career Programs", "Knowledge", "Laboratories", "Lead", "Legal patent", "Link", "Lipids", "Malignant neoplasm of prostate", "Manuscripts", "Mediating", "Mediation", "Medical Students", "Medical center", "Mentors", "Mesenchymal Stem Cells", "Mitochondria", "Molecular", "Names", "Neurosciences", "Obesity", "Oklahoma", "Oncogenes", "Oncology", "Ophthalmology", "Pathologic", "Patients", "Peer Review", "Pharmaceutical Preparations", "Pharmacology", "Phosphatidylglycerols", "Physiological", "Physiology", "Population", "Positioning Attribute", "Principal Investigator", "Process", "Production", "Program Evaluation", "Program Research Project Grants", "Psoriasis", "Publications", "Published Comment", "Publishing", "Puerto Rican", "Request for Applications", "Research", "Research Institute", "Research Personnel", "Role", "Science", "Scientist", "Services", "Signal Pathway", "Signal Transduction", "Signaling Molecule", "Skin", "Skin Carcinoma", "Societies", "Sodium Chloride", "Soldier", "System", "Training", "United States Food and Drug Administration", "United States National Institutes of Health", "Universities", "Very low density lipoprotein", "Veterans", "Work", "Zona Glomerulosa", "aldosterone hypertension", "anticancer research", "aquaporin 3", "blood pressure regulation", "bone", "career", "cell growth", "colon cancer treatment", "combat", "corneal epithelial wound healing", "corneal epithelium", "cost", "editorial", "high risk", "interest", "keratinocyte", "lectures", "medical schools", "meetings", "member", "novel", "pandemic disease", "phospholipase D2", "posters", "professor", "programs", "protein kinase D", "recruit", "response", "skin disorder", "symposium" ], "approved": true } }, { "type": "Grant", "id": "6710", "attributes": { "award_id": "1I01HX003082-01A2", "title": "The EMBER Trial for Weight Management Engagement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-02-01", "end_date": "2025-08-31", "award_amount": null, "principal_investigator": { "id": 22453, "first_name": "Jessica Yelena", "last_name": "Breland", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1497, "ror": "", "name": "VETERANS ADMIN PALO ALTO HEALTH CARE SYS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1497, "ror": "", "name": "VETERANS ADMIN PALO ALTO HEALTH CARE SYS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Almost 40% of Veterans using the Veterans Health Administration (VA) have obesity, putting millions at risk for costly and debilitating conditions, including diabetes, cancer, and severe COVID-19. VA weight management programs effectively reduce weight, morbidity, and mortality. For example, MOVE!, VA’s flagship program for weight management is associated with reductions in cardiovascular disease and diabetes. However, while 94% of eligible Veterans are offered weight management programs, less than 8% use them. Motivational interviewing improves treatment engagement, but clinicians have limited time to apply it. Therefore, we developed EMBER, a self-directed tool with the goal of Enhancing Motivation for Better Engagement and Reach for weight management. It is available in paper and digital formats. EMBER is not a weight management program, instead it engages Veterans in existing programs by informing and guiding choices about weight management. EMBER is the product of an HSR&D Career Development Award (15-257). Significance: If EMBER increases engagement in effective weight management programs, it has the potential to help Veterans lose weight, thereby improving health and quality of life for thousands of patients. As a result, we address many HSR&D priorities, e.g., access to care, virtual care, healthy equity, & primary care. Innovation & Impact: EMBER is the first self-directed, motivational interviewing-based intervention designed to increase Veteran engagement in weight management programs. As opposed to a “one-off” study in a specific population, the proposed work takes a novel, low-touch population health approach that could be translated to other programs (e.g., behavioral pain management). EMBER also includes vignettes relevant to populations at high risk for obesity (e.g., women, people of color). Further, t he Hybrid Type 1 design will ensure results can be scaled and sustained while also advancing implementation science. As such, the proposed work will: 1) advance the science of engagement in behavioral health programs and 2) facilitate future research on the implementation of EMBER and similar interventions. Specific Aims: 1. Assess whether Veterans randomized to EMBER are more likely to have any weight management engagement at 2-month follow-up (per administrative data supplemented with self-report) compared to those randomized to the control arm (information sheet listing available programs). (Primary Outcome) 2. Assess whether Veterans randomized to EMBER have greater weight management program retention, weight management behaviors (e.g., physical activity), weight loss, and quality of life gains at 6-month follow-up compared to those randomized to the control arm. (Secondary Outcomes) 3. Assess factors likely to affect EMBER’s implementation. Preliminary implementation outcomes will be assessed via RE-AIM4 (Reach, Effectiveness, Implementation) and the Proctor et al.5 implementation outcomes framework (Acceptability, Appropriateness, Costs, Fidelity). (Implementation Outcomes) Randomized two site Hybrid Type 1 Effectiveness-Implementation Trial among Veteran primary care patients with obesity in VA (N=470). Participants will be randomized to EMBER or a control condition consisting of a list of available weight management programs. The primary outcome is any weight management engagement 2-months after baseline. Aims 1 and 2 will use self-report and administrative data to assess intervention outcomes. Aim 3 will use patient data and information from research staff. Methodology: Implementation/Next Steps: If effective, we will use implementation strategies suggested by Aim 3 to ensure Veterans receive EMBER. We will test these strategies in a Hybrid Type 2 trial to understand EMBER’s effectiveness in real world contexts and best practices for dissemination and implementation of EMBER and similar interventions.", "keywords": [ "Address", "Affect", "Behavior", "Behavioral", "Belief", "Body Weight decreased", "Cardiovascular Diseases", "Cardiovascular system", "Cessation of life", "Color", "Complications of Diabetes Mellitus", "Data", "Diabetes Mellitus", "Disease", "Dissemination and Implementation", "Effectiveness", "Ensure", "Exercise", "Food Services", "Goals", "Health", "Health Promotion", "Health Services Accessibility", "Health Services Administration", "Heart Diseases", "Hybrids", "Intervention", "Interview", "K-Series Research Career Programs", "Letters", "Malignant Neoplasms", "Methodology", "Methods", "Modeling", "Morbidity - disease rate", "Motivation", "Obesity", "Organization and Administration", "Outcome", "Pain management", "Paper", "Participant", "Patient Self-Report", "Patient-Centered Care", "Patients", "Persons", "Physical activity", "Pilot Projects", "Population", "Primary Health Care", "Quality of life", "Randomized", "Research", "Research Design", "Research Priority", "Risk", "Science", "Self Efficacy", "Self-Direction", "Series", "Services", "Site", "System", "Testing", "Time", "Touch sensation", "Translating", "United States", "United States Health Resources Administration", "Veterans", "Veterans Health Administration", "Weight", "Weight Gain", "Weight maintenance regimen", "Woman", "Work", "arm", "base", "behavioral health", "comorbidity", "cost", "design", "digital", "disorder prevention", "effectiveness implementation trial", "flexibility", "follow-up", "health equity", "health service use", "high risk", "high risk population", "hybrid type 1 design", "hybrid type 1 trial", "hybrid type 2 trial", "implementation outcomes", "implementation science", "implementation strategy", "improved", "innovation", "interest", "mortality", "motivational enhancement therapy", "novel", "nutrition", "obese patients", "obesity risk", "patient oriented", "people of color", "physical conditioning", "population health", "primary outcome", "programs", "secondary outcome", "self help", "severe COVID-19", "smoking cessation", "therapy design", "tool", "virtual healthcare" ], "approved": true } }, { "type": "Grant", "id": "6716", "attributes": { "award_id": "5U01DP006583-02", "title": "Georgia Pregnancy Risk Assessment Monitoring System (PRAMS) Project", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-05-01", "end_date": "2026-04-30", "award_amount": 160019, "principal_investigator": { "id": 22467, "first_name": "Joseph M", "last_name": "Bryan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1498, "ror": "", "name": "GEORGIA STATE DEPARTMENTOF PUBLIC HEALTH", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1498, "ror": "", "name": "GEORGIA STATE DEPARTMENTOF PUBLIC HEALTH", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Georgia Pregnancy Risk Assessment Monitoring System (PRAMS) Project is a statewide, ongoing population‐based survey that collects information on women with a recent live birth in Georgia. Georgia PRAMS initiated sampling with January 1993 births. PRAMS survey data complements Vital Records data by collecting information about mothers’ attitudes, behaviors, and experiences before, during, and shortly after pregnancy. Survey topics include preconception health, pregnancy intention, prenatal care, health insurance, oral health during pregnancy, substance use, breastfeeding, safe sleep behaviors and environment, intimate partner violence, maternal stressors, contraception use and methods, and supplemental topics as emergent public health issues arise (ex: Zika Virus, Coronavirus Disease 2019), among others. Each month, a stratified random sample of approximately 110 women is drawn from birth certificate records accessed through the State Office of Vital Records. The current stratification variable is preterm birth (gestational age greater than 20 and less than 37 weeks versus all other births). The stratification scheme can vary by year and is used to ensure adequate representation of key subgroups in the sample. Sampled PRAMS participants are surveyed two to six months after delivery of their infant first by mail and then by phone if a mail survey response is not received. Each mother’s survey is linked to her infant’s birth certificate. The goal of the Georgia PRAMS Project is to provide population-based data on maternal experiences and behaviors before, during, and after pregnancy and during early infancy which can be used to reduce the risk of adverse birth outcomes and improve the health of mothers and infants in Georgia. Georgia PRAMS is the only data source for many key indicators of maternal and child health in the state, providing essential data to identify disparities, select maternal and child health priorities, inform and evaluate programs, and inform policy changes to improve the health of all mothers and infants in Georgia.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6723", "attributes": { "award_id": "5I01BX005466-02", "title": "Covid-19: Fast-tracking treatment by exploiting the steroid hormone receptor/TMPRSS2 axis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-01", "end_date": "2023-03-31", "award_amount": null, "principal_investigator": { "id": 22480, "first_name": "Kerry L.", "last_name": "Burnstein", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1500, "ror": "", "name": "MIAMI VA HEALTH CARE SYSTEM", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1500, "ror": "", "name": "MIAMI VA HEALTH CARE SYSTEM", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19 poses a tremendous health threat, particularly to individuals overrepresented in the US Veteran community. COVID-19 mortality is greater in men than in women; while this disparity is at least partially due to factors such as higher rates of smoking, a hormonal link is likely and can be rapidly tested therapeutically by repurposing existing drugs. The viral etiologic agent of COVID-19, SARS-CoV-2 (CoV-2), attaches to human airway epithelium via the viral spike (S) protein, which binds to angiotensin-converting enzyme 2 (ACE2) on the host cell surface. Viral entry requires S protein cleavage by the serine protease TMPRSS2, which is a known transcriptional target of the androgen receptor (AR). Lung epithelial cells (a target of CoV-2 infection) express transcriptionally active AR. We hypothesize that AR up-regulates TMPRSS2 in lung epithelial cells and thereby promotes viral entry and infectivity. We propose that FDA-approved AR antagonists will decrease CoV-2 entry and spread and can be rapidly repurposed for COVID-19. IL-6 is the major cytokine released in moderate and severe COVID-19 cases and both published and our preliminary data show that IL-6 enhances AR transcriptional activity. We will therefore also examine the contribution of interleukin 6 (IL-6) to AR regulation of TMPRRS2. To facilitate these studies in a robust manner, we propose to isolate the SARS-CoV-2 entry mechanism through the use of luciferase-expressing pseudovirions that harbor the SARS-CoV-2 S protein. Such a reporter system has high reproducibility, versatility and dynamic range, allowing for the rapid, accurate and specific assessment of a large range of viral entry regulators into primary human lung epithelial cells and lung adenocarcinoma cell lines under BSL2+ conditions. We will test whether AR inhibition reduces TMPRSS2 and the requisite S protein processing thereby decreasing CoV-2 entry into host lung epithelial cells. Subsequently, we will confirm results on a subset of promising compounds using live SARS-Cov-2 in an approved BSL3 facility. Safe and effective AR antagonists are FDA approved for prostate cancer and this study will provide rationale to repurpose these drugs for use in clinical trials for COVID-19. The glucocorticoid receptor (GR) shares a common DNA response element consensus sequence with AR. Furthermore, GR upregulation of TMPRSS2 has been shown in advanced prostate cancer. Therefore, in parallel, we will examine whether TMPRSS2 is regulated by glucocorticoids (cortisol) and blocked by a GR antagonist in models of human lung epithelia. Patients taking corticosteroids (including the elderly and individuals with diabetes, hypertension and chronic inflammatory disease) are at the highest risk of death from COVID-19. The World Health Organization has provided interim guidance to avoid glucocorticoids in COVID- 19 patients with severe acute respiratory distress syndrome. Therefore, understanding GR regulation of TMPRSS2 is also essential to repurposing the TMPRSS2-inhibitory FDA-approved agents for COVID-19. Our aims are to: (1) Evaluate steroid hormone receptor (AR and GR) regulation of TMPRSS2 in human primary airway and lung epithelial cells and lung adenocarcinoma cell line models and (2) Examine the capacity of FDA-approved AR and GR antagonists to block CoV-2 entry and infectivity in human primary airway and lung epithelial cells. US Veterans represent several demographics acutely afflicted by COVID-19. Older US Veterans are particularly vulnerable because of higher comorbidities including smoking, diabetes, heart disease and hypertension. Burden on the Veteran community is also proportionally higher given the propensity for poor outcome in men as compared to women following COVID-19 infection. Since the anti-androgen therapies to be tested are FDA approved for prostate cancer treatment and have also been used safely in women with breast cancer, our study has potential for immediate impact to all veterans.", "keywords": [ "2019-nCoV", "ACE2", "Acute", "Acute Respiratory Distress Syndrome", "Address", "Adrenal Cortex Hormones", "Affect", "Agonist", "Androgen Antagonists", "Androgen Receptor", "Antiandrogen Therapy", "Binding", "COVID-19", "COVID-19 mortality", "COVID-19 patient", "COVID-19 treatment", "Cell Line", "Cell surface", "Clinical Trials", "Collaborations", "Colorado", "Communities", "Consensus Sequence", "DNA", "Data", "Diabetes Mellitus", "Disease", "Drug usage", "Elderly", "Enrollment", "Epithelial", "Epithelial Cells", "Etiology", "FDA approved", "Genetic Transcription", "Glucocorticoid Receptor", "Glucocorticoids", "Health", "Health Personnel", "Heart Diseases", "Hormonal", "Human", "Hydrocortisone", "Hypertension", "Individual", "Infection", "Interdisciplinary Study", "Interleukin-6", "Ligands", "Link", "Luciferases", "Lung", "Lung Adenocarcinoma", "Malignant neoplasm of prostate", "Measures", "Modeling", "Nuclear Receptors", "Outcome", "Patients", "Pattern", "Pharmaceutical Preparations", "Pharmacological Treatment", "Prostate Cancer therapy", "Proteins", "Proteolysis", "Publishing", "Receptor Inhibition", "Regulation", "Reporter", "Reproducibility", "Research", "Resistance", "Response Elements", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "Serine Protease", "Smoking", "Stanolone", "System", "TMPRSS2 gene", "Testing", "Therapeutic", "Universities", "Veterans", "Viral", "Virus", "Woman", "World Health Organization", "advanced prostate cancer", "airway epithelium", "biosafety level 3 facility", "castration resistant prostate cancer", "chronic inflammatory disease", "comorbidity", "cytokine", "demographics", "drug repurposing", "glucocorticoid receptor alpha", "high risk", "human model", "loved ones", "mRNA Expression", "male", "malignant breast neoplasm", "men", "protein expression", "receptor upregulation", "response", "severe COVID-19", "steroid hormone receptor", "therapeutic evaluation", "transcriptome", "viral entry inhibitor" ], "approved": true } }, { "type": "Grant", "id": "6757", "attributes": { "award_id": "5I01BX005432-02", "title": "COVID-19: Elucidating the Role of the NasalEpithelium in SARS-CoV-2 Infection, Transmission, and Prevention", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-01-01", "end_date": "2022-12-31", "award_amount": null, "principal_investigator": { "id": 22556, "first_name": "Noam A", "last_name": "Cohen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1488, "ror": "https://ror.org/03j05zz84", "name": "Philadelphia VA Medical Center", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1488, "ror": "https://ror.org/03j05zz84", "name": "Philadelphia VA Medical Center", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe acute respiratory syndrome coronavirus SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19) has led to a pandemic with a mortality of approximately 3.5% and a wide range of morbidity outcomes negatively impacted by pre-existing conditions. Given the prevalence of pre-existing comorbid conditions in Veterans, it is imperative to understand the mechanisms of how SARS-CoV-2 invades and replicates within the barrier defense cells of the nose, which is the primary portal for viral entry. Furthermore, current data suggests that the nasal carriage functions as a potential reservoir for viral persistence and transmission (i.e., shedding) at times that are both prior to and during the manifestation of severe respiratory symptoms. This project utilizes a unique biobank of cryopreserved nasal cells collected from over 1000 individuals over 15 years to understand the critical issues surrounding SARS-CoV-2 interaction with the human nasal epithelia. Paradoxically, while SARS-CoV-2 can be detected in nasal swabs prior to its detection in sputum, there is a paucity of rhinologic symptoms (<5% with nasal congestion) associated with COVID-19, with the exception of reversible anosmia in 30-70% of patients. This is particularly problematic because up to 25% of infected individuals remain asymptomatic, but can continue to spread SARS-CoV-2 through airborne droplets. This work seeks to elucidate both the mechanisms controlling which epithelial cell lineages become infected with virus and the type of immune response generated within infected or neighboring epithelia. Through this approach, we will shed light on the issue of why certain individuals never develop symptoms while others progress to severe respiratory failure and death. We will focus on the SARS-CoV-2 receptor Angiotensin Converting Enzyme 2 (ACE2), which is essential and sufficient for the virus to enter cells. Our preliminary data generated from single cell RNA analysis of primary human sinonasal tissue demonstrates that ACE2 is expressed in discrete clusters of nasal epithelia. ACE2- specific immunostaining of human nasal epithelial cells ex vivo and primary ciliated air liquid interface (ALI) cultures corroborates the sc-RNAseq data. Furthermore, our data show that inoculation of primary ALI cultures with SARS-CoV-2 results in approximately 1%-25% of cells becoming infected, suggesting a selective process. These data indicate that we are uniquely poised to test the hypothesis that ACE2 expressing cells constitute a unique reservoir of viral replication and are likely to mount an inflammatory cytokine response that is distinct from non-infected epithelia. Using our established team of experts in nasal epithelial cell biology, viral pathogenesis, inflammatory cytokine biology and genetics we will determine the following: A) which types of epithelia are virally infected, B) what are the local inflammatory cascades in infected vs. non-infected cells, and C) will pharmacologic manipulation of the epithelial innate defense pathways significantly alter SARS-CoV-2 ability to infect, replicate and be released from human nasal epithelia. Successful completion of this work is likely to have a major impact on development of novel strategies to combat COVID19 disease progression within the general population and especially in the U.S. Veteran population.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Affect", "Age", "Air", "Anosmia", "Apical", "Asthma", "Basal Cell", "Biology", "Bronchitis", "COVID-19", "Caring", "Cell Lineage", "Cells", "Cellular biology", "Cessation of life", "Chronic Obstructive Pulmonary Disease", "Collaborations", "Communities", "Congestive", "Cryopreservation", "Data", "Detection", "Development", "Disease Progression", "Double-Stranded RNA", "Epithelial", "Epithelial Cells", "Functional disorder", "Future", "Gender", "General Population", "Genetic", "Genotype", "Goals", "Goblet Cells", "Growth", "Harvest", "Health", "Healthcare Systems", "Human", "Immune", "Immune response", "Immunologic Receptors", "Individual", "Infection", "Inflammatory", "Inflammatory Response Pathway", "Invaded", "Kinetics", "Knowledge", "Lead", "Light", "Liquid substance", "Malignant neoplasm of lung", "Medical", "Morbidity - disease rate", "Mucins", "Mucous Membrane", "Mucous body substance", "Nasal Epithelium", "Natural Immunity", "Nitric Oxide", "Nose", "Nucleocapsid Proteins", "Outcome", "Pathway interactions", "Patients", "Pennsylvania", "Peptide Hydrolases", "Pharmacology", "Predisposition", "Prevalence", "Prevention", "Process", "Production", "Prophylactic treatment", "Protocols documentation", "Pulmonary Emphysema", "RNA analysis", "Race", "Resources", "Respiration Disorders", "Respiratory Disease", "Respiratory Failure", "Respiratory Signs and Symptoms", "Respiratory Tract Infections", "Rhinitis", "Role", "SARS coronavirus", "SARS-CoV-2 infection", "Sampling", "Sinusitis", "Sputum", "Symptoms", "TMPRSS2 gene", "Testing", "Time", "Tissues", "Type 2 Angiotensin II Receptor", "Universities", "Veterans", "Viral", "Viral Genome", "Viral Pathogenesis", "Viral reservoir", "Virus", "Virus Diseases", "Virus Replication", "Virus Shedding", "Vulnerable Populations", "Work", "airway epithelium", "antimicrobial peptide", "asthma exacerbation", "biobank", "biosafety level 3 facility", "burden of illness", "combat", "comorbidity", "cytokine", "demographics", "discrete time", "experimental study", "high risk", "in vitro Model", "innate immune pathways", "insight", "military veteran", "mortality", "nasal swab", "novel strategies", "pandemic disease", "particle", "prophylactic", "racial disparity", "receptor", "screening", "single-cell RNA sequencing", "success", "targeted treatment", "transcriptome sequencing", "transmission process", "ultraviolet irradiation" ], "approved": true } }, { "type": "Grant", "id": "6779", "attributes": { "award_id": "5I01RX003666-02", "title": "Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs (LAUREL Study)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-01-01", "end_date": "2024-12-31", "award_amount": null, "principal_investigator": { "id": 22583, "first_name": "Kristina Anne", "last_name": "Crothers", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1512, "ror": "", "name": "VA PUGET SOUND HEALTHCARE SYSTEM", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22584, "first_name": "Aaron P.", "last_name": "Turner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1512, "ror": "", "name": "VA PUGET SOUND HEALTHCARE SYSTEM", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 (SARS2) infection, which leads to COVID-19, is a global pandemic. Chronic lung disease (CLD), particularly chronic obstructive pulmonary disease (COPD), has emerged as a risk factor for infection and severity of COVID-19. Currently, very little is known of the long-term consequences of COVID-19 and how factors such as CLD, other comorbidities and social determinants of health (SDOH) influence the trajectory of recovery in survivors. While similar complications for COVID-19 survivors and risk factors for poor health recovery may be expected as in other causes of pneumonia and critical illness, long term outcomes of COVID- 19 have not been characterized or quantified. Patients who are hospitalized and critically ill are anticipated to have greater functional deficits, but even those with mild and moderate COVID-19 may have significant impacts on function given systemic involvement of infection; rehabilitation needs may be more likely to be under-recognized and unmet in many of these patients. Overall, functional outcomes may be worse than expected in all COVID-19 patients because of prolonged length of illness and barriers to receiving rehabilitation services, including restricted face-to-face interactions, limited capacity, and limited access for many. Because CLD is associated with increased frailty and impaired function, patients with CLD may be particularly vulnerable not only to infection but also sequalae of COVID-19. Given the current physical distancing environment, we urgently need a new paradigm for rehabilitation of patients recovering from COVID-19 that can inform and apply to other causes of pneumonia as well. In this proposal we will determine patient rehabilitation needs across the spectrum of severity of COVID-19, assessing if needs differ by CLD, comorbidity burden, SDOH or other patient risk factors. We will also assess the feasibility and acceptability of a novel, virtually-delivered, home-based personalized telerehabilitation program for survivors of COVID-19 that contains a COVID Reactivation and Engagement (CORE) intervention with exercise and dyspnea management and additional personalized modules based on patient needs. We will recruit patients treated for COVID-19 as outpatients or discharged directly home for this program. We have a multidisciplinary team with expertise in rehabilitation medicine, psychology, pulmonary, critical care, nursing, complementary and integrative health, quantitative and qualitative observational research and clinical trials, and will accomplish three separate aims: 1) Determine patient factors associated with severity and complications of COVID-19 utilizing VA EHR data; 2) Determine self-reported functional outcomes and trajectory of recovery after COVID- 19 in a prospective study using mixed methods; and 3) Examine the feasibility and acceptability of a virtually- delivered, home-based rehabilitation intervention for survivors of COVID-19, with components based on an individual patient’s needs. Results will characterize the recovery from COVID-19 and identify rehabilitation and care needs across domains of services that can be offered within VA. Our pilot study will inform larger trials to test the efficacy of this newly-developed program to improve functioning, reduce secondary symptoms, and improve quality of life among individuals recovering from COVID-19.", "keywords": [ "Acute", "Admission activity", "Anxiety", "COVID-19", "COVID-19 complications", "COVID-19 patient", "COVID-19 severity", "COVID-19 survivors", "COVID-19 treatment", "Cardiac", "Cardiovascular system", "Caregivers", "Caring", "Cessation of life", "Chronic", "Chronic Obstructive Pulmonary Disease", "Chronic lung disease", "Classification", "Clinical", "Clinical Trials", "Cognition", "Cognitive", "Complementary Health", "Coronavirus", "Critical Illness", "Data", "Dialysis procedure", "Disease", "Dyspnea", "Dyspnea Management", "Electronic Health Record", "Environment", "Event", "Exercise", "Future", "Health", "Healthcare Systems", "Home", "Hospitalization", "Hospitals", "Impairment", "Individual", "Infection", "Influenza", "Inpatients", "Integrative Medicine", "Intensive Care Units", "International", "Intervention", "Interview", "Location", "Lung", "Mental Depression", "Mental Health", "Methods", "Nurses", "Observational Study", "Outcome", "Outpatients", "Oxygen", "Pain", "Patient Recruitments", "Patient Self-Report", "Patient risk", "Patient-Focused Outcomes", "Patients", "Personal Satisfaction", "Physical Function", "Physical Medicine", "Pilot Projects", "Pneumonia", "Predisposition", "Prospective Studies", "Psychology", "Quality of life", "Recovery", "Rehabilitation therapy", "Reporting", "Risk", "Risk Factors", "SARS-CoV-2 infection", "Services", "Severities", "Stroke", "Surveys", "Survivors", "Symptoms", "Syndrome", "Time", "Veterans", "Veterans Health Administration", "acceptability and feasibility", "base", "community acquired pneumonia", "comorbidity", "coronavirus disease", "critical care nursing", "design", "disability", "efficacy testing", "feasibility testing", "follow-up", "frailty", "functional outcomes", "health administration", "health related quality of life", "hospital readmission", "illness length", "improved", "improved functioning", "individual patient", "infection risk", "long term consequences of COVID-19", "mortality", "multidisciplinary", "novel", "pandemic disease", "pilot test", "programs", "prospective", "rehabilitation paradigm", "rehabilitation service", "rehabilitative care", "satisfaction", "social health determinants", "telerehabilitation", "uptake", "virtual delivery" ], "approved": true } }, { "type": "Grant", "id": "6788", "attributes": { "award_id": "1R13FD007552-01", "title": "13th International Bordetella Symposium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 22597, "first_name": "Madilyn", "last_name": "Gonzalez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2023-03-31", "award_amount": 15000, "principal_investigator": { "id": 22598, "first_name": "Fredrick Heath", "last_name": "Damron", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1093, "ror": "https://ror.org/011vxgd24", "name": "West Virginia University", "address": "", "city": "", "state": "WV", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1093, "ror": "https://ror.org/011vxgd24", "name": "West Virginia University", "address": "", "city": "", "state": "WV", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Whooping cough, also known as Pertussis, is a respiratory disease caused by the bacterial pathogen Bordetella pertussis. Pertussis is one of the world’s leading causes of vaccine-preventable deaths and is currently the only vaccine-preventable bacterial disease that is increasing in incidence. Despite high vaccine coverage, whooping cough (pertussis) has re-emerged as a major public health concern in the US and the world. Recently, it was estimated that there were 24 million pertussis cases and 160,700 deaths in children younger than 5 years around the world per year. In addition to being added to the NIH emerging infectious pathogens list in 2015, the CDC recently listed Bordetella pertussis on its new Watch List in the 2019 Antibiotic Resistance Threats Report because of the unknown future burden of this highly contagious bacterium. Since the 1960’s, the Bordetella research community has organized an International Bordetella Symposium, the 12th symposium was hosted at Brussels University by Dr. Camille Locht, in April of 2019. In an effort to increase dissemination of new data and exchange of ideas, Dr. Ciaran Skerry hosted the 1st ever Bordetella Research Day at the University of Maryland in April, 2018. The Bordetella Research Day was meant to be a U.S-based conference for Bordetella researchers to meet during the off years of the International Bordetella Symposiums. Due to the COVID-19 pandemic, both the 2020 Bordetella Research Day, and the 2021 International Bordetella Symposium were postponed. To continue dissemination of important research, the International Bordetella Society hosted a zoom-based conference in August 2020 which garnered attendance from academia, the CDC, FDA, NIH, and many pharmaceutical companies. The major success of this online event resulted in the Bordetella Society creating a monthly Lab Meeting Series, where different groups around the world can showcase their latest research. In order to further support the development of the next generation of scientists, this R13 application is requesting funds from the FDA Center for Biologics Evaluations and Research (CBER) to support travel associated costs for junior scientists (pre- and post-doctoral) to attend and present innovative research at the 13th International Bordetella Symposium hosted at the University of British Columbia in Vancouver, Canada (June 2022).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6799", "attributes": { "award_id": "1R03HS028069-01A1", "title": "Advancing Health Policy and Systems Approaches to Improved Delivery of Surgical Limb Salvage Procedures for Severe Chronic Wounds", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 22615, "first_name": "Brent", "last_name": "Sandmeyer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2023-09-30", "award_amount": 100000, "principal_investigator": { "id": 22616, "first_name": "Derek", "last_name": "DeLia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1515, "ror": "", "name": "MEDSTAR HEALTH RESEARCH INSTITUTE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22617, "first_name": "Kenneth L", "last_name": "Fan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1515, "ror": "", "name": "MEDSTAR HEALTH RESEARCH INSTITUTE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "In the United States, 2.4-4.5 million people suffer from chronic lower extremity wounds, costing the health system up to $31.7 billion annually. A multidisciplinary approach is necessary for amputation reduction in severe wounds, as nontraumatic amputation leads to a 5-year mortality rate of 50-75%. It has been demonstrated that the establishment of limb salvage centers reduces amputation rates, improves provider to provider education resulting in earlier referral, improves prevention measures and increases global functioning of patients. Currently, little is known about the state of limb salvage adoption by hospitals in the United States, including which surgical modalities are most commonly used, their spread across regions and over time, and the scale of operations relative to community-based need. Even less is known about how this care is organized within local hospital markets and how the structure of these markets affects which patients receive limb salvage versus amputations. This lack of fundamental knowledge stands as a barrier to improvements in the organization and distribution of resource-intensive wound care teams to treat chronic wounds in the U.S. As a result, limb salvage is characterized by fragmented delivery, inequitable provision, few quality standards, and pervasive fee-for-service payment mechanisms with their well-known lack of incentives for quality or efficiency. These issues are likely to grow in importance during the COVID-19 pandemic, as delays in care will likely lead to more patients developing severe chronic wounds before seeking treatment. This project will address these gaps by conducting the first large-scale assessment of limb salvage spread, provision, and market effects for lower extremity wounds in the United States. Under Aim 1, will use the 2005-2017 Healthcare Cost and Utilization Project (HCUP) – State Inpatient Database (SID) linked to the American Hospital Annual (AHA) Survey to examine the role of hospital market structure, hospital factors, and patient factors in the adoption and spread of limb salvage procedures and its effects on disparities in care. Under Aim 2, we will engage an Expert Advisory Panel to help translate the findings from Aim 1 into a set of actionable health system and policy strategies, disseminate findings to practitioners, and develop a research agenda for advancing much-needed healthcare payment and delivery reforms in the provision of severe chronic wound care. This study will advance AHRQ’s priority to spread evidence-based practices and develop the foundation to address other priorities including comparative performance of systems and providers, and development of performance-improvement incentives. These findings will be especially important to AHRQ priority populations, including low-income, minority, rural, and people with chronic illnesses.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6801", "attributes": { "award_id": "5I01BX005447-02", "title": "Immune mediated lung injury in COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-01", "end_date": "2023-03-31", "award_amount": null, "principal_investigator": { "id": 21877, "first_name": "Jane C", "last_name": "Deng", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1477, "ror": "https://ror.org/05eq41471", "name": "Veterans Health Administration", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 and the disease it causes (COVID-19) has emerged as a major global public health threat in the span of a few months. In particular, SARS-CoV-2 adds to the present number of acute respiratory infections, including influenza and bacterial pneumonia, which are endangering the health of our veterans and aging population. In particular, severe COVID-19 disease is characterized by severe lung injury, which results in severely impaired oxygen delivery and ultimately multiple organ failure and death. Our ongoing research has focused on a population of white blood cells called neutrophils, which are the most abundant white blood cell in our body and which have been shown to be a pivotal immune cell that contributes greatly to lung injury. However, our current medical knowledge is inadequate for understanding what neutrophils do in the context of viral infection. Although neutrophils are critical for eliminating many types of infections, they are believed to be a major contributor to the development of lung injury, and how to balance their beneficial activities with their harmful functions is poorly understood. Therefore, a better understanding of how neutrophils behavior and phenotype are altered during severe SARS-CoV-2 and other viral infections would aid in developing novel therapies to improve their antimicrobial functions, while limiting their injurious effects. The research we propose in this grant will examine how well neutrophils eliminate SARS-CoV-2 viruses, or if they are an excessively activated population of immune cells recruited to the lung whose harmful activities outweighs their benefits. We also will test an exciting new treatment approach developed by our collaborator at UCLA to see if this can block the damaging effects of neutrophils on lung cells, while blocking viral replication. The results of this 2-year project will provide insights into the beneficial versus harmful contributions of neutrophils in the development of severe COVID-19 disease, and potentially identify new therapies to benefit veterans and other vulnerable patients.", "keywords": [ "2019-nCoV", "Acute", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Acute respiratory infection", "Age", "Animal Model", "Antiviral Agents", "Apoptosis", "Bacterial Pneumonia", "COVID-19", "COVID-19 pandemic", "Cardiopulmonary", "Cell Death", "Cells", "Cessation of life", "Chronic", "Coculture Techniques", "Collaborations", "Coronavirus", "Coronavirus Infections", "Data", "Development", "Disease", "Elderly", "Epithelial Cells", "Equilibrium", "Exposure to", "Failure", "Funding", "Grant", "Health", "Histones", "Host Defense", "Human", "Immune", "Immune response", "Immunology", "Immunotherapy", "Impairment", "In Vitro", "Infection", "Inflammation", "Inflammation Mediators", "Inflammatory Response", "International", "Knowledge", "Lead", "Leukocytes", "Literature", "Lung", "Lung infections", "Mechanical ventilation", "Mediating", "Mediator of activation protein", "Medical", "Modeling", "Morbidity - disease rate", "Mouse Strains", "Multiple Organ Failure", "Murine hepatitis virus", "Mus", "Natural Killer Cells", "Oxygen", "Pathogenesis", "Pathogenicity", "Pathology", "Patients", "Peptides", "Play", "Population", "Positioning Attribute", "Public Health", "Pulmonary Pathology", "Reporting", "Research", "Research Proposals", "Resolution", "Risk", "Risk Factors", "Role", "SARS-CoV-2 immunity", "SARS-CoV-2 infection", "Severe Acute Respiratory Syndrome", "Testing", "Veterans", "Viral", "Virus", "Virus Diseases", "Virus Replication", "Virus Shedding", "aging population", "antimicrobial", "antiviral immunity", "base", "behavioral phenotyping", "comorbidity", "cytotoxicity", "design", "extracellular", "fighting", "global health", "improved", "in vivo", "influenza pneumonia", "insight", "lung development", "lung injury", "male", "military veteran", "mortality", "neutrophil", "novel", "novel therapeutics", "pathogen", "patient population", "preservation", "prevent", "recruit", "repaired", "response", "severe COVID-19" ], "approved": true } }, { "type": "Grant", "id": "6809", "attributes": { "award_id": "5U01DP006612-02", "title": "Component A [Core]: Massachusetts Pregnancy Risk Assessment Monitoring System (PRAMS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-05-01", "end_date": "2026-04-30", "award_amount": 160020, "principal_investigator": { "id": 22627, "first_name": "Hafsatou", "last_name": "Diop", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1517, "ror": "", "name": "MASSACHUSETTS STATE DEPT OF PUB HEALTH", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1517, "ror": "", "name": "MASSACHUSETTS STATE DEPT OF PUB HEALTH", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "PI / PD: Diop, Hafsatou RFA-DP-21-001 Project Summary/Abstract The overall goal of the Massachusetts Pregnancy Risk Assessment Monitoring System (PRAMS) is to collect data to improve the health of mothers in the preconception, perinatal, or postpartum periods and the health of their infants. Massachusetts (MA) has implemented PRAMS since 2007 and oversamples women by race/ethnicity to allow women of color to have a greater opportunity to participate in the survey. PRAMS methodology uses a mixed mode survey (mail and telephone) to inquire about maternal attitudes, experiences and behaviors before, during and shortly after pregnancy. There are approximately 70,000 births annually in MA, of which 2,400 are sampled for inclusion in PRAMS. During the last three years for which we have weighted data, the overall weighted response rate was 59.9%, 61.9%, and 62.4%, for 2016, 2017, and 2018, respectively. MA PRAMS response rates have been consistently above the CDC minimum response rate threshold of 55% during 2016-2018. PRAMS will be used to inform the Title V priorities and performance measures, and support MA maternal and child health (MCH) priorities. We propose to use PRAMS to provide reliable data to inform MCH programs with limited or nonexistent data. For example, although MA has taken a number of steps to understand and respond to the opioid epidemic, data on prescription pain relievers and other opioids during pregnancy, particularly among women who have not been diagnosed or treated for substance use disorder were lacking, as they are not captured in administrative and program data. In addition, data on whether women received substance use disorder treatment from providers including medication-assisted treatment (MAT) during pregnancy were limited. We will use the PRAMS Opioid Survey and Opioid Call-Back Survey (OCBS) to obtain these data among new mothers. In addition, the OCBS will provide a unique opportunity to ask about access to substance misuse treatment, including MAT, rehabilitation services, and other programs such as peer-to-peer support systems, and to identify best practices to mitigate the risk of opioid misuse in the postpartum period and reduce maternal opioid misuse and overdose events. Similarly, in response to the current pandemic, MA is also working on implementing a COVID-19 survey to better understand the inequities we see in the spread and treatment of COVID-19.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1424, "count": 14236 } } }